Post-Conference Perspectives: Recent Advances in the Management of Chronic GvHD - Episode 5

Understanding Mechanisms of Action: Ruxolitinib, Ibrutinib, and Belumosudil

August 2, 2023

Preet M. Chaudhary, MD, PhD, Noah Merin, MD, PhD

Dr. Merin describes the mechanisms of action of ruxolitinib, ibrutinib, and belumosudil and shares clinical pearls for community oncologists on methods for achieving response with these agents.

EP. 1: The Chronic GvHD Landscape: Risk Factors and Diagnosis

EP. 2: First-line Treatment for Patients with Chronic GvHD

EP. 3: Defining and Managing Steroid Refractory Chronic GvHD

EP. 4: Role of Ruxolitinib in Steroid-Refractory Chronic GvHD

Now Viewing

EP. 5: Understanding Mechanisms of Action: Ruxolitinib, Ibrutinib, and Belumosudil

EP. 6: Key Efficacy Data of Ibrutinib and Belumosudil in Steroid-Refractory Chronic GvHD Patients

EP. 7: Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD

EP. 8: Future Directions in Chronic GvHD